FDA and USP Independently Agree: A Single HPLC Result Is Not Enough to Confirm Peptide Identity
核心洞察
The FDA and the U.S. Pharmacopeial Convention (搜索) independently conclude that a single HPLC retention time is insufficient to confirm the identity of a research peptide.
Both authorities require at least two orthogonal identification procedures, covering sequence, structure, aggregation state, and biological activity, under ICH Q6A criteria.
A 2023 Pharmaceutical Research paper states a single chromatographic retention time "is not considered extremely specific," while a 2026 review corroborates that impurities at 0.10% or greater must be identified using UHPLC-HRMS.
A single HPLC retention time is not enough to confirm the identity of a research peptide, according to an Oath Research (搜索) analysis of federal guidance and peer-reviewed standards literature. The U.S. Food and Drug Administration (搜索) (FDA) and the U.S. Pharmacopeial Convention (搜索)'s (USP) own standards scientists arrive at the same conclusion separately, neither citing the other, pointing to a settled position across the field rather than one regulator's preference. The convergence matters because it comes from two different kinds of authority: a federal regulator setting drug-approval requirements and a standards body that writes the reference specifications laboratories use to calibrate their own testing.
The FDA's 2021 guidance on highly purified synthetic peptide drug products lists four distinct categories of orthogonal characterization needed to establish a peptide's identity: primary sequence and physicochemical properties, secondary structure, oligomer or aggregation state, and biological activity. A 2023 paper in Pharmaceutical Research, co-authored by staff from USP and the UK's Medicines & Healthcare products Regulatory Agency, names the same four attributes independently and states plainly that a single chromatographic retention time "is not considered extremely specific." The paper puts a number on the standard: at least two orthogonal procedures should be used to identify a peptide under ICH Q6A's regulatory criteria.
The FDA guidance also recommends high-resolution mass spectrometry that can be paired with chromatography, rather than standalone HPLC, for impurity characterization, since HPLC UV detection alone confirms that something eluted at a given time, not what that something is. A 2026 review in the Journal of Pharmaceutical Investigation independently corroborates both figures: peptide-related impurities at 0.10% or greater of the drug substance must be identified, and UHPLC-HRMS is the recommended method for detecting and characterizing them.
What the Convergence Means for Sourcing
Oath Research (搜索) frames this as a sourcing question as much as an analytical one. If two independent authorities require orthogonal identity confirmation on top of purity testing, researchers evaluating a peptide supplier have a concrete standard to check against: does the batch documentation show one method, or at least two? A Certificate of Analysis (COA) that reports only a purity percentage answers part of the question that a peptide's identity raises, not the whole of it.
This distinction matters because purity and identity measure different factors. A material can register a high purity percentage on a chromatogram while the underlying compound is misidentified or degraded in ways a single retention time would not reveal. Pairing HPLC with an independent identity method closes that gap, which is why the FDA and McCarthy et al. both treat the pairing as a baseline rather than an enhancement.
Oath Research's Testing Approach
Oath Research (搜索) applies both categories that the FDA and McCarthy et al. describe to its research-peptide batches: high-performance liquid chromatography for purity and mass spectrometry for identity confirmation, conducted by an independent U.S.-based laboratory. Each vial typically carries a batch number that researchers can enter on the Oath Research Peptides page to retrieve the Certificate of Analysis for that specific lot, rather than a generic product specification. Recent batches document purity above 99%. Oath Research states that all products are supplied strictly for laboratory and research use and are not intended for human consumption.
Methodology
Oath Research (搜索)'s findings are based on the FDA's 2021 synthetic-peptide guidance, McCarthy et al. (Pharmaceutical Research, 2023), and a 2026 Journal of Pharmaceutical Investigation review, cross-referenced against Oath Research's published batch-testing procedures.
Founded in 2025 and headquartered in Gilbert, Arizona, Oath Research (搜索) supplies research peptides supported by independently verified, batch-specific Certificates of Analysis. The company publishes public COAs linked to individual batch numbers to promote transparency in laboratory sourcing and quality verification.